Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 157

1.

Trichuris suis therapy in Crohn's disease.

Summers RW, Elliott DE, Urban JF Jr, Thompson R, Weinstock JV.

Gut. 2005 Jan;54(1):87-90.

2.

Trichuris suis seems to be safe and possibly effective in the treatment of inflammatory bowel disease.

Summers RW, Elliott DE, Qadir K, Urban JF Jr, Thompson R, Weinstock JV.

Am J Gastroenterol. 2003 Sep;98(9):2034-41.

PMID:
14499784
3.

Trichuris suis therapy for active ulcerative colitis: a randomized controlled trial.

Summers RW, Elliott DE, Urban JF Jr, Thompson RA, Weinstock JV.

Gastroenterology. 2005 Apr;128(4):825-32.

PMID:
15825065
4.

Defining the optimal response criteria for the Crohn's disease activity index for induction studies in patients with mildly to moderately active Crohn's disease.

Thia KT, Sandborn WJ, Lewis JD, Loftus EV Jr, Feagan BG, Steinhart AH, Hanauer SB, Persson T, Sands BE.

Am J Gastroenterol. 2008 Dec;103(12):3123-31. doi: 10.1111/j.1572-0241.2008.02176.x.

PMID:
18786111
5.

Iatrogenic Trichuris suis infection in a patient with Crohn disease.

Kradin RL, Badizadegan K, Auluck P, Korzenik J, Lauwers GY.

Arch Pathol Lab Med. 2006 May;130(5):718-20.

PMID:
16683891
6.

A phase 2 study of allogeneic mesenchymal stromal cells for luminal Crohn's disease refractory to biologic therapy.

Forbes GM, Sturm MJ, Leong RW, Sparrow MP, Segarajasingam D, Cummins AG, Phillips M, Herrmann RP.

Clin Gastroenterol Hepatol. 2014 Jan;12(1):64-71. doi: 10.1016/j.cgh.2013.06.021. Epub 2013 Jul 19.

PMID:
23872668
7.

Therapeutic colonization with Trichuris suis.

Summers RW, Elliott DE, Weinstock JV.

Arch Pathol Lab Med. 2006 Dec;130(12):1753; author reply 1753-4. No abstract available.

PMID:
17149943
8.

A phase 1/2A trial of STA 5326, an oral interleukin-12/23 inhibitor, in patients with active moderate to severe Crohn's disease.

Burakoff R, Barish CF, Riff D, Pruitt R, Chey WY, Farraye FA, Shafran I, Katz S, Krone CL, Vander Vliet M, Stevens C, Sherman ML, Jacobson E, Bleday R.

Inflamm Bowel Dis. 2006 Jul;12(7):558-65.

PMID:
16804392
9.

Extracorporeal photopheresis for the treatment of refractory Crohn's disease: results of an open-label pilot study.

Abreu MT, von Tirpitz C, Hardi R, Kaatz M, Van Assche G, Rutgeerts P, Bisaccia E, Goerdt S, Hanauer S, Knobler R, Mannon P, Mayer L, Ochsenkuhn T, Sandborn WJ, Parenti D, Lee K, Reinisch W; Crohn's Disease Photopheresis Study Group.

Inflamm Bowel Dis. 2009 Jun;15(6):829-36. doi: 10.1002/ibd.20833.

PMID:
19130617
10.

Sargramostim for active Crohn's disease.

Korzenik JR, Dieckgraefe BK, Valentine JF, Hausman DF, Gilbert MJ; Sargramostim in Crohn's Disease Study Group.

N Engl J Med. 2005 May 26;352(21):2193-201.

11.

Autologous bone marrow-derived mesenchymal stromal cell treatment for refractory luminal Crohn's disease: results of a phase I study.

Duijvestein M, Vos AC, Roelofs H, Wildenberg ME, Wendrich BB, Verspaget HW, Kooy-Winkelaar EM, Koning F, Zwaginga JJ, Fidder HH, Verhaar AP, Fibbe WE, van den Brink GR, Hommes DW.

Gut. 2010 Dec;59(12):1662-9. doi: 10.1136/gut.2010.215152. Epub 2010 Oct 4.

PMID:
20921206
12.

[Therapeutic effects of combined enteral nutrition with Tripterygium Wilfordii poly-glycoside in remission induction of active adult Crohn's disease].

Gong JF, Niu LY, Wei XW, Zhu WM, Li N, Li JS.

Zhonghua Wai Ke Za Zhi. 2009 Aug 15;47(16):1213-7. Chinese.

PMID:
19781164
13.

Safety and efficacy of antigen-specific regulatory T-cell therapy for patients with refractory Crohn's disease.

Desreumaux P, Foussat A, Allez M, Beaugerie L, H├ębuterne X, Bouhnik Y, Nachury M, Brun V, Bastian H, Belmonte N, Ticchioni M, Duchange A, Morel-Mandrino P, Neveu V, Clerget-Chossat N, Forte M, Colombel JF.

Gastroenterology. 2012 Nov;143(5):1207-17.e1-2. doi: 10.1053/j.gastro.2012.07.116. Epub 2012 Aug 8.

PMID:
22885333
14.

Comparison of two adalimumab treatment schedule strategies for moderate-to-severe Crohn's disease: results from the CHARM trial.

Colombel JF, Sandborn WJ, Rutgeerts P, Kamm MA, Yu AP, Wu EQ, Pollack PF, Lomax KG, Chao J, Mulani PM.

Am J Gastroenterol. 2009 May;104(5):1170-9. doi: 10.1038/ajg.2009.59. Epub 2009 Apr 7.

PMID:
19352339
15.

Long-term management of Crohn's disease with mesalamine capsules (Pentasa). Pentasa Crohn's Disease Compassionate Use Study Group.

Hanauer SB, Krawitt EL, Robinson M, Rick GG, Safdi MA.

Am J Gastroenterol. 1993 Sep;88(9):1343-51.

PMID:
8362827
16.

An update on the use of helminths to treat Crohn's and other autoimmunune diseases.

Reddy A, Fried B.

Parasitol Res. 2009 Jan;104(2):217-21. doi: 10.1007/s00436-008-1297-5. Epub 2008 Dec 3. Review.

PMID:
19050918
17.

[Helminths and inflammatory bowel diseases].

Laclotte C, Oussalah A, Rey P, Bensenane M, Pluvinage N, Chevaux JB, Trouilloud I, Serre AA, Boucekkine T, Bigard MA, Peyrin-Biroulet L.

Gastroenterol Clin Biol. 2008 Dec;32(12):1064-74. doi: 10.1016/j.gcb.2008.04.030. Epub 2008 Jul 10. French.

18.

Randomized, controlled trial of recombinant human interleukin-11 in patients with active Crohn's disease.

Sands BE, Winston BD, Salzberg B, Safdi M, Barish C, Wruble L, Wilkins R, Shapiro M, Schwertschlag US; RHIL-11 Crohn's Study group.

Aliment Pharmacol Ther. 2002 Mar;16(3):399-406.

19.

Thalidomide therapy for patients with refractory Crohn's disease: an open-label trial.

Ehrenpreis ED, Kane SV, Cohen LB, Cohen RD, Hanauer SB.

Gastroenterology. 1999 Dec;117(6):1271-7.

PMID:
10579967
20.
Items per page

Supplemental Content

Write to the Help Desk